Description
Maximizing bacterial eradication is a key goal in the selection of appropriate antimicrobial therapy in respiratory tract infection.
By using only amoxicillin it is not possible to completely eradicate the micro organisms. Because some of the bacterium develops resistance by secreting an enzyme known as β-lactamase, which destroys the beta lactam ring of amoxicillin & thus the bacteria is not killed.
Clavulanic acid is a beta-lactamase inhibitor which when combined with amoxicillin extends the antibacterial activity of amoxicillin to beta-lactamase-producing strains, which are otherwise resistant.
Clavulanic acid is adequately absorbed after oral administration and its basic pharmacokinetic characteristics are similar to those of amoxicillin.
Indications
LRTI : Bacterial Pneumonia, Acute Bronchitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease(COPD), Bronchiectasis
Skin and soft tissue infections: Impetigo, Furuncles and Carbuncles, Ecthyma, Erysipelas, Cellulitis
Urinary Tract Infection (U.T.I) : Pyelonephritis, Cystitis, Urethritis etc.
Composition
Each 5ml of reconstituted suspension contains:
Amoxycillin Trihydrate IP
equivalent to Amoxycillin
400 mg
Potassium Clavulanate Diluted IP
equivalent to clavulanic Acid
57mg